Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

7 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000040363	2020-11-23	2020-11-28	Clinical study of cerebrospinal fluid immunoglobulin G oligoclonal band detection in Chinese patients with multiple sclerosis	Clinical study of cerebrospinal fluid immunoglobulin G oligoclonal band detection in Chinese patients with multiple sclerosis	Multiple Sclerosis	Gold Standard:Isoelectric focusing electrophoresis;Index test:(1) CSF IgG index (2) CSF 24-hour intrathecal synthesis rate (3) CSF-OCB testing type (4) CSF-OCB positive rate;	Huashan Hospital, Fudan University	NULL	Recruiting	14	65	Both	Target condition:180;Difficult condition:90	N/A	China
2	ChiCTR2000034098	2020-07-01	2020-06-23	A New Quantitative Method Used to Evaluate Cervical Spinal Cord Damage in Multiple Sclerosis: Diffusional Kurtosis Imaging Research	A New Quantitative Method Used to Evaluate Cervical Spinal Cord Damage in Multiple Sclerosis: Diffusional Kurtosis Imaging Research	Multiple Sclerosis	Gold Standard:Conventional cervical MRI;Index test:Diffusional Kurtosis Imaging;	The First Hospital of Jilin University	NULL	Pending			Both	Target condition:48;Difficult condition:0		China
3	NCT03993171 (ClinicalTrials.gov)	December 19, 2019	31/5/2019	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.	A Phase 2, Open-Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis.	Relapsing Remitting Multiple Sclerosis	Drug: gold nanocrystals	Clene Nanomedicine	University of Texas Southwestern Medical Center	Recruiting	18 Years	55 Years	All	30	Phase 2	United States
4	NCT03536559 (ClinicalTrials.gov)	November 23, 2018	2/5/2018	Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis	A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis;Optic Neuropathy;Optic; Neuritis, With Demyelination	Drug: CNM-Au8;Drug: Placebo	Clene Nanomedicine	Clene Australia Pty Ltd	Active, not recruiting	18 Years	55 Years	All	76	Phase 2	United States;Australia;Canada
5	NCT04120675 (ClinicalTrials.gov)	November 9, 2018	24/9/2019	Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis	The Effects of Early Harvest Extra Virgin Olive Oil on Cognition and Mental Health of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis Patients	Progressive Multiple Sclerosis	Dietary Supplement: Early Harvest Extra Virgin Olive Oil	Aristotle University Of Thessaloniki	Greek Alzheimer's Association and Related Disorders;Ellis-Farm, Eliama Daily Value Gold (ellis-farm.com)	Completed	18 Years	65 Years	All	30	N/A	Greece
6	ChiCTR-DND-17013749	2017-12-01	2017-12-07	Application of 3.0 T MRI 3D sequences of CUBE-T2 FLAIR?DIR for brain lesions of childhood-onset multiple sclerosis	Application of 3.0 T MRI 3D sequences of CUBE-T2 FLAIR?DIR for brain lesions of childhood-onset multiple sclerosis	childhood-onset multiple sclerosis	Gold Standard:CUBE-T2 FLAIR scanning;Index test:DIR scanning;	Children's Hospital of Chongqing Medical University	NULL	Recruiting			Both	Target condition:80;Difficult condition:0		China
7	EUCTR2010-024017-31-IT (EUCTR)	15/03/2011	08/02/2011	A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy - GOLDEN	A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy - GOLDEN	Relapsing Remitting Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399	Product Name: FINGOLIMOD Product Code: FTY720D Trade Name: EXTAVIA INN or Proposed INN: Interferon beta -1b Trade Name: AVONEX INN or Proposed INN: Interferon beta -1a Trade Name: COPAXONE INN or Proposed INN: Glatiramer acetate	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes			Italy